Diabetes is a leading cause of disease and death in the United States. More than 29 million Americans are living with diabetes, and 86 million are living with prediabetes, a serious health condition that increases a person’s risk of type 2 diabetes and other chronic diseases. In 2014, nearly 9.3 percent of all deaths for persons over the age of 25 were among people with diabetes. The prevalence of diabetes and overweight (one of the major risk factors for diabetes) continue to increase. Substantial new efforts to prevent or control diabetes have begun, including the Diabetes Prevention Trial and the National Diabetes Education Program.
Participants aged 12 years and older, who were examined in the morning session, were eligible.
Insulin is the primary hormone responsible for controlling glucose metabolism, and its secretion is determined by plasma glucose concentration. The insulin molecule is synthesized in the pancreas as pro-insulin and is later cleaved to form C-peptide and insulin. The principal function of insulin is to control the uptake and utilization of glucose in the peripheral tissues. Insulin concentrations are severely reduced in insulin-dependent diabetes mellitus (IDDM) and some other conditions, while insulin concentrations are raised in non-insulin-dependent diabetes mellitus (NIDDM), obesity, and some endocrine disorders.
The Elecsys 2010 Insulin chemiluminescent “sandwich” immunoassay employs two monoclonal antibodies; which together are specific for human insulin. During the first incubation, a 20 μL serum sample, a biotinylated monoclonal insulin-specific antibody, and a monoclonal insulin-specific antibody labeled with a ruthenium complex (Tris [2, 2’-bipyridyl]ruthenium(II)-complex (Ru(bpy)) form a sandwich complex. During the second incubation, after the addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell. Application of a voltage to the electrode then induces chemiluminescent emission, which is measured by a photomultiplier. The amount of light produced is directly proportional to the amount of insulin in the sample.
Refer to the Laboratory Method Files section for a detailed description of the laboratory methods used.
There were no changes to the lab method, lab equipment, or lab site for this component in the NHANES 2015-2016 cycle.
Insulin (June 2018)
Serum samples are processed, stored, and shipped to the University of Missouri-Columbia, Columbia, MO for analysis.
Detailed instructions on specimen collection and processing are discussed in the NHANES Laboratory Procedures Manual (LPM). Vials are stored under appropriate frozen (-30oC) conditions until they are shipped to the University of Missouri – Columbia for testing.
The NHANES quality assurance and quality control (QA/QC) protocols meet the 1988 Clinical Laboratory Improvement Act mandates. Detailed QA/QC instructions are discussed in the NHANES LPM.
Mobile Examination
Centers (MECs)
Laboratory team performance is monitored using several techniques. NCHS and
contract consultants use a structured competency assessment evaluation during
visits to evaluate both the quality of the laboratory work and the quality control
procedures. Each laboratory staff member is observed for equipment operation,
specimen collection and preparation; testing procedures and constructive
feedback are given to each staff member. Formal retraining sessions are
conducted annually to ensure that required skill levels were maintained.
Analytical
Laboratories
NHANES uses several methods to monitor the quality of the analyses performed by
the contract laboratories. In the MEC, these methods include performing blind
split samples collected on “dry run” sessions. In addition, contract
laboratories randomly perform repeat testing on 2% of all specimens.
NCHS developed and distributed a quality control protocol for all CDC and contract laboratories, which outlined the use of Westgard rules (Westgard et al, 1981) when running NHANES specimens. Progress reports containing any problems encountered during shipping or receipt of specimens, summary statistics for each control pool, QC graphs, instrument calibration, reagents, and any special considerations are submitted to NCHS quarterly. The reports are reviewed for trends or shifts in the data. The laboratories are required to explain any identified areas of concern.
The data were reviewed. Incomplete data or improbable values were sent to the performing laboratory for confirmation.
One variable was created in this data file using the following formula:
LBXIN and LBDINSI:
The insulin value in µU/mL (LBXIN) was converted to pmol/L (LBDINSI) by
multiplying by 6.0 (rounded to 2 decimals).
Refer to the 2015-2016 Laboratory Data Overview for general information on NHANES laboratory data.
Subsample Weights
Insulin were measured in a fasting subsample of persons 12 years and older. Special sample weights are required to analyze these data properly. Specific sample weights for this subsample are included in this data file and should be used when analyzing these data.
Demographic and Other Related Variables
The analysis of NHANES laboratory data must be conducted using the appropriate survey design and demographic variables. The NHANES 2015-2016 Demographics File contains demographic data, health indicators, and other related information collected during household interviews as well as the sample design variables. The recommended procedure for variance estimation requires use of stratum and PSU variables (SDMVSTRA and SDMVPSU, respectively) in the demographic data file.
The Fasting Questionnaire File includes auxiliary information such as fasting status, the length of fast, and the time of venipuncture
This laboratory data file can be linked to the other NHANES data files using the unique survey participant identifier SEQN.
Detection Limits
The detection limits were constant for all of the analytes in the data set. Two variables are provided for each of these analytes. The variable name ending “LC” (ex., LBDINLC) indicates whether the result was below the limit of detection: the value “0” means that the result was at or above the limit of detection, “1” indicates that the result was below the limit of detection. For analytes with analytic results below the lower limit of detection (ex., LBDINLC=1), an imputed fill value was placed in the analyte results field. This value is the lower limit of detection divided by the square root of 2 (LLOD/sqrt[2]). The other variable prefixed LBX (ex., LBXIN) provides the analytic result for that analyte.
The lower limit of detection (LLOD, in uU/mL) for insulin is:
Variable Name |
SAS Label |
LLOD |
LBXIN |
Insulin |
1.0 |
Please refer to the NHANES Analytic Guidelines and the on-line NHANES Tutorial for further details on the use of sample weights and other analytic issues.
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
13612.331812 to 521632.18583 | Range of Values | 2743 | 2743 | |
0 | No Lab Result | 448 | 3191 | |
. | Missing | 0 | 3191 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
0.71 to 324.06 | Range of Values | 2921 | 2921 | |
. | Missing | 270 | 3191 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
4.26 to 1944.36 | Range of Values | 2921 | 2921 | |
. | Missing | 270 | 3191 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
0 | 0 | 2920 | 2920 | |
1 | 1 | 1 | 2921 | |
. | Missing | 270 | 3191 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
0 to 37 | Range of Values | 3135 | 3135 | |
. | Missing | 56 | 3191 |
Code or Value | Value Description | Count | Cumulative | Skip to Item |
---|---|---|---|---|
0 to 59 | Range of Values | 3135 | 3135 | |
. | Missing | 56 | 3191 |